| Phase 3 |
| NCT04853342 |
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With… |
Non-small Cell Lung Carcinoma |
Recruiting |
2026-08-13 |
| NCT06416410 |
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… |
Advanced Non-squamous Non-small-cell Lung Cancer |
Recruiting |
2026-08-13 |
| NCT06956001 |
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With… |
EGFR |
Recruiting |
2026-08-13 |
| NCT06970639 |
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus… |
NSCLC Patients With Brain Metastasis |
Recruiting |
2026-08-13 |
| NCT07010419 |
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant… |
NSCLC |
Recruiting |
2026-08-13 |
| NCT03787992 |
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic… |
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer |
Active, Not Recruiting |
2025-04-11 |
| Phase 2 |
| NCT06008288 |
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic… |
KRAS P.G12C |
Recruiting |
2026-03-13 |
| NCT05466149 |
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic… |
NSCLC |
Active, Not Recruiting |
2026-08-14 |
| Phase 1/2 |
| NCT05276726 |
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11… |
Non-small Cell Lung Cancer |
Recruiting |
2026-08-13 |
| NCT05288205 |
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors… |
KRAS P.G12C |
Recruiting |
2026-08-13 |
| NCT05009329 |
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C… |
NSCLC |
Active, Not Recruiting |
2026-08-13 |
| NCT05194995 |
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid… |
Advanced Colorectal Cancer |
Active, Not Recruiting |
2026-03-16 |
| Phase 1 |
| NCT06955988 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303… |
Locally Advanced or Metastatic Non-small Cell Lung Cancer |
Recruiting |
2026-08-13 |